Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

Literature DB >> 16239238

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

A du Bois¹, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, M Bookman, D Bowtell, M Brady, A Casado, A Cervantes, E Eisenhauer, M Friedlaender, K Fujiwara, S Grenman, J P Guastalla, P Harper, T Hogberg, S Kaye, H Kitchener, G Kristensen, R Mannel, W Meier, B Miller, J P Neijt, A Oza, R Ozols, M Parmar, S Pecorelli, J Pfisterer, A Poveda, D Provencher, E Pujade-Lauraine, M Randall, J Rochon, G Rustin, S Sagae, F Stehman, G Stuart, E Trimble, P Vasey, I Vergote, R Verheijen, U Wagner.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2005 PMID： 16239238 DOI： 10.1093/annonc/mdi961

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

Keyword Cloud
Cited

× No keyword cloud information.

103 in total

1. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors: Seiya Sato; Hiroaki Itamochi
Journal: Ther Adv Med Oncol Date: 2014-11 Impact factor: 8.168

Review 2. Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors: Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal: Clin Transl Oncol Date: 2010-06 Impact factor: 3.405

3. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.

Authors: Mark A Morgan; Michael W Sill; Keiichi Fujiwara; Benjamin Greer; Stephen C Rubin; Koen Degeest; S Diane Yamada; Steven Waggoner; Robert L Coleman; Joan L Walker; Robert S Mannel
Journal: Gynecol Oncol Date: 2011-02-01 Impact factor: 5.482

4. Chemotherapy: Current drugs still have potential in advanced ovarian cancer.

Authors: Thomas Hogberg
Journal: Nat Rev Clin Oncol Date: 2010-04 Impact factor: 66.675

5. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Authors: Petronella O Witteveen; Koen J C van der Mijn; Maartje Los; Roelien H Kronemeijer; Gerard Groenewegen; Emile E Voest
Journal: Neoplasia Date: 2010-11 Impact factor: 5.715

6. Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.

Authors: Paulette Mhawech-Fauceglia; Dan Wang; Damanzoopinder Samrao; Grace Kim; Kate Lawrenson; Teodulo Meneses; Song Liu; Annie Yessaian; Tanja Pejovic
Journal: Cancer Microenviron Date: 2013-11-10

7. Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer.

Authors: Manizheh Sayyah-Melli; Gita Kashi Zonoozi; Shahryar Hashemzadeh; Ali Esfahani; Elaheh Ouladehsahebmadarek; Mehry Jafary Shobeiry; Parvin Mostafa Garabaghi; Azhough Ramin
Journal: J Obstet Gynaecol India Date: 2013-08-14